Suppr超能文献

一类新型解旋酶抑制剂N,N'-双[4-(1H(2H)-苯并三唑-1(2)-基)苯基]烷基二羧酸酰胺的合成及其抗小核糖核酸病毒科体外活性

Synthesis and anti-picornaviridae in vitro activity of a new class of helicase inhibitors the N,N'-bis[4-(1H(2H)-benzotriazol-1(2)-yl)phenyl] alkyldicarboxamides.

作者信息

Carta A, Loriga M, Piras S, Paglietti G, Ferrone M, Fermeglia M, Pricl S, La Colla P, Collu G, Sanna T, Loddo R

机构信息

Dipartimento Farmaco Chimico Tossicologico, via Muroni 23/a, 07100 Sassari, Italy.

出版信息

Med Chem. 2007 Nov;3(6):520-32. doi: 10.2174/157340607782360308.

Abstract

A series N,N'-bis[4-(1H(2H)-benzotriazol-1(2)-yl)phenyl]alkyldicarboxamides (3a-f and 5a-j) were prepared starting from their already known (1a-d) and (4a-c) or new (4d) amine parents. Because of the antiviral activity of several N-[4-(1H(2H)-benzotriazol-1(2)-yl)phenyl]alkylcarboxamides previously reported, title compounds were evaluated in vitro for cytotoxicity and antiviral activity against viruses representative of Picornaviridae, [i.e. Enterovirus Coxsackie B2 (CVB-2) and Polio (Sb-1)] and of two of the three genera of the Flaviviridae [Bovine Viral Diarrhea Virus (BVDV) and Yellow Fever Virus (YFV)]. Furthermore, because of the in silico activity against the RNA-dependent RNA-helicase of Polio 1 previously reported, title compounds were evaluated against the 3D model of the Sb-1 helicase and against the 2D model of the CVB-2 helicase. As a reference we used the antiviral and in silico activities of an imidazo counterpart of the title compounds, N,N'-bis[4-(2-benzimidazolyl)phenyl]alkyldicarboxamides (III) that other authors reported to be able to inhibit the corresponding enzyme of Hepatitis C Virus (HCV). In cell-based antiviral assays, N,N'-bis[4-(1H-benzotriazol-1-yl)phenyl]alkyldicarboxamides (3a-f) resulted completely inactive whereas the bis-5,6-dimethyl-benzotriazol-2-yl derivatives (5d-f) exhibited good activity against the Enteroviruses, (EC(50)s ranged between 7 and 11 microM against CVB-2 and 19-52 against Sb-1). Interestingly, bis-5,6-dichloro-benzotriazol-2-yl derivatives (5h-j) showed very selective activity against CVB-2 (EC(50)s = 4-11 microM) whereas they resulted completely inactive against all the other viruses screened. In general, all title compounds showed a good cytotoxicity profile in MT-4 cells. Molecular modeling investigations showed that active compounds may interact with the binding site of the Sb-1 helicase and that their free binding energy values are in agreement with their EC(50)s values.

摘要

一系列N,N'-双[4-(1H(2H)-苯并三唑-1(2)-基)苯基]烷基二羧酰胺(3a - f和5a - j)是从它们已知的(1a - d)和(4a - c)或新的(4d)胺母体开始制备的。由于先前报道的几种N-[4-(1H(2H)-苯并三唑-1(2)-基)苯基]烷基羧酰胺具有抗病毒活性,因此对标题化合物进行了体外细胞毒性评估以及针对小RNA病毒科代表性病毒[即肠道病毒柯萨奇B2 (CVB - 2)和脊髓灰质炎病毒(Sb - 1)]以及黄病毒科三个属中的两个属的病毒[牛病毒性腹泻病毒(BVDV)和黄热病病毒(YFV)]的抗病毒活性评估。此外,由于先前报道的对脊髓灰质炎病毒1的RNA依赖性RNA解旋酶的计算机模拟活性,对标题化合物针对Sb - 1解旋酶的3D模型和CVB - 2解旋酶的2D模型进行了评估。作为参考,我们使用了标题化合物的咪唑类似物N,N'-双[4-(2 - 苯并咪唑基)苯基]烷基二羧酰胺(III)的抗病毒和计算机模拟活性,其他作者报道该类似物能够抑制丙型肝炎病毒(HCV)的相应酶。在基于细胞的抗病毒试验中,N,N'-双[4-(1H - 苯并三唑-1 - 基)苯基]烷基二羧酰胺(3a - f)完全无活性,而双-5,6 - 二甲基 - 苯并三唑-2 - 基衍生物(5d - f)对肠道病毒表现出良好的活性,(对CVB - 2的EC(50)值在7至11 microM之间,对Sb - 1的EC(50)值在19至52之间)。有趣的是,双-5,6 - 二氯 - 苯并三唑-2 - 基衍生物(5h - j)对CVB - 2表现出非常选择性的活性(EC(50)值 = 4 - 11 microM),而对所有其他筛选的病毒完全无活性。总体而言,所有标题化合物在MT - 4细胞中显示出良好的细胞毒性特征。分子模拟研究表明,活性化合物可能与Sb - 1解旋酶的结合位点相互作用,并且它们的自由结合能值与它们的EC(50)值一致。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验